There is expected to be a great deal of news flow from Imugene (ASX: IMU) as it looks to quickly attract the attention of a big pharma partner looking to bring effective cancer treatments to market.
The $33 million-capped IMU is currently developing immuno-oncology therapies and is moving ahead at a significant pace, having recently received notice that the Canadian Patent Office had issued a Grant Notice for this next generation cancer therapy that will protect specific cancer vaccination formulations for commercial interest.
IMU’s frontrunner drug candidate HER-Vaxx, is already in Phase 1b and Phase 2 trials and is interestingly further advanced than Regeneron’s cancer therapies before Regeneron was acquired for $1.6 billion by Roche.
IMU is looking to attract big pharma’s attention by 2020.
HER-Vaxx targets the same receptor as the two leading antibody drugs on the market, Herceptin and Perjeta, with annual sales of US$8.2 billion in a markety predicted to generate sales of US$36 billion by 2025.
IMU is looking to commercialise a treatment that has improved efficacy over existing treatments and is more cost efficient, which would give it a strong position in this market.
The information in this email should not be the only trigger for your investment decision. Click on the link below for a more in-depth and informed examination of the company. We strongly recommend you seek professional financial advice whenever making financial investment decisions.
HER-Vaxx isn’t IMU’s only play here. It is also working with Arginine, a critical amino acid for the health of cancer fighting T-cells.
Again, IMU will be looking to replicate recent deals done in the space including a deal struck recently between $25 billion-capped Incyte and Calithera Biosciences in which $53 million was paid up front by Incyte.
As IMU is working off the same premise, could we see this $37.8 million capped company climb higher?